Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

133P - The role of determining the diagnostic value of circulating tumor DNA (ctDNA) and natural blood killers (NK) in the diagnosis of precancerous diseases of the colon and colorectal cancer (CRC)

Date

27 Jun 2024

Session

Poster Display session

Presenters

Innara Turkpenova

Citation

Annals of Oncology (2024) 35 (suppl_1): S1-S74. 10.1016/annonc/annonc1477

Authors

I. Turkpenova1, D. Kaidarova2, K.K. Smagulova1, A. Jumanov1, M. Orazgalieva1, Z. Amankulov1, R. Kadyrbaeva3

Author affiliations

  • 1 Kazakh Research Institute of Oncology and Radiology-KazIOR, Almaty/KZ
  • 2 Kazakh Research Institute of Oncology & Radiology-KazIOR, Almaty/KZ
  • 3 Kazakh Reserch Institute of Oncology & Radiology, Almaty/KZ

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 133P

Background

The role of determining the diagnostic value of circulating tumor DNA (ctDNA) and natural blood killers (NK) in the diagnosis of precancerous diseases of the colon and colorectal cancer (CRC) ctDNA and NK indicate disorders in the immune system, can be detected in the blood of patients long before clinical signs of cancer appear and allow treatment to begin at an early stage. The aim was to study NK and ctDNA activity data.

Methods

A liquid biopsy was performed to determine ctDNA – 150studies, and a test to determine the activity of NK (NKVue test) – 600. The isolation of ctDNA from plasma was carried out using the QIAamp Circulating Nucleic Acid Kit. Using the digital PCR system in QIAcuity One nanoplanets (Qiagen), KRAS gene mutations were analyzed (c.34G>C, c.35G>T, c.35G>A, c.35G>C, c.34G>T, c.37G>A, c.38G>C, c.34G>A, c.38G>T) and BRAF (V600E) by digital PCR. QIAcuity Nanoplate 26k 24-well nanoplates and dPCR LNA Mutation Assay reagents were used. The average age is 61.0±4.1 years.

Results

The 600 participants were divided into four groups: the control group (67.8%,407/600), progressive adenomas (PA) (21.1%,127/600), inflammatory bowel disease (IBD) (8.9%,53/600) and CRC (2.2%,13/600). The median activity (MA) of NK cells in patients with CRC was the lowest and =127.0pg/ml (mean value (NW) 166.8pg/ml). In patients with IBD, the level of NK cell activity was reduced (MA – 317.8pg/ml, CP – 498.0pg/ml). The MA of NK cells in individuals with PA =282pg/ml (CP – 594.7pg/ml). In the control group, the MA of NK cells was higher than in the other groups -628.8pg/ml with a PH of -871.0pg/ml. The negative optical density (OP) of determining the activity of NK cells = 0.4 and 1.1 in the diagnosis of CRC and PA, when +OP is 2.5 and 1.0. +likelihood ratio >5 indicates a high probability of disease, whereas OP <5 has little significance. KRAS and BRAF mutations were determined in the ctDNA group. A KRAS mutation was detected in plasma samples from 120 patients, one each in codons 13 and 61, and in 30 patients in codon 12. The V600E BRAF mutation was found in 10 patients.

Conclusions

A study the combination of ctDNA and NK activity can be a useful tool in the early diagnosis and monitoring of PA and CRC.

Legal entity responsible for the study

I. Tirkpenova.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.